MedTrace Logo

Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients

NCT00254787 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-06-11

No results posted yet for this study

Summary

The purpose of the study is to compare the safety and tolerability of IR (Immediate-Release) quetiapine in a rapid escalation scheme with to the current approved label titration.

Conditions

Interventions

DRUG

IR (Immediate-Release) quetiapine fumarate (drug)

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Germany Medical Director · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Completion
2006-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00254787 on ClinicalTrials.gov